This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Theuer, C. P. Articles by Pastan, I. Search for Related Content PubMed PubMed Citation Articles by Theuer, C. P. Articles by Pastan, I.

Immunotoxins Made with a Recombinant Form of Pseudomonas Exotoxin A That Do Not Require Proteolysis for Activity

Laboratory of Molecular Biology, National Cancer Institute, Division of Cancer Biology, Diagnosis and Centers, NIH, Bethesda, Maryland 20892

We used recombinant DNA technology to construct a mutant form of Pseudomonas exotoxin A (PE) called cysPE35 that contains amino acids 280–364 and 381–613 of PE. cysPE35 begins at the native PE proteolytic cleavage site and contains a single cysteine residue at position 287 that can be used to conjugate the toxin to monoclonal antibodies (MAbs). Unlike immunotoxins containing larger mutant forms of PE, such as PE40 or PE38, immunotoxins containing cysPE35 linked through a disulfide bond do not require proteolysis to generate a toxin fragment able to translocate to the cytosol. cysPE35 was conjugated to several MAbs and their activities were studied in vitro and in vivo. The concentration of toxin that inhibited protein synthesis as measured by a decrease in [³H]leucine incorporation of 50% of cysPE35 conjugated through a disulfide bond to the MAb HB21, which targets the human transferrin receptor, was 1 ng/ml on A431 cells. The MAb HB21 conjugated through a thioether bond to cysPE35 was much less active (concentration of toxin that inhibited protein synthesis as measured by a decrease in [³H]leucine incorporation of 50%, 200 ng/ml). An immunotoxin containing PE38 conjugated through either a disulfide or thioether bond to the MAb HB21 had a concentration of toxin that inhibited protein synthesis as measured by a decrease in [³H]leucine incorporation of 50% of 5 ng/ml, indicating that proteolysis of PE38 may be rate limiting in the action of these immunotoxins. Two other MAbs, LL2 and B3, were also conjugated through a disulfide bond to cysPE35. Both immunotoxins were also more active against cultured cells than conjugates using PE38 or PE40, and caused complete regression of human tumor xenografts growing in nude mice. In conclusion, we have constructed a mutant form of PE which must be coupled to MAbs through a disulfide bond to produce fully active immunotoxins that do not require proteolysis to generate a toxin fragment able to reach the cell cytosol.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 9/10/92. Accepted 10/28/92.

This article has been cited by other articles:

				K. Matsushita, I. Margulies, M. Onda, S. Nagata, M. Stetler-Stevenson, and R. J. Kreitman Soluble CD22 as a tumor marker for hairy cell leukemia Blood, September 15, 2008; 112(6): 2272 - 2277. [Abstract] [Full Text] [PDF]

				S. M. Thomas, Q. Zeng, M. W. Epperly, W. E. Gooding, I. Pastan, Q. C. Wang, J. Greenberger, and J. R. Grandis Abrogation of Head and Neck Squamous Cell Carcinoma Growth by Epidermal Growth Factor Receptor Ligand Fused to Pseudomonas Exotoxin Transforming Growth Factor {alpha}-PE38 Clin. Cancer Res., October 15, 2004; 10(20): 7079 - 7087. [Abstract] [Full Text] [PDF]

				Y.-M. Xu, L.-F. Wang, L.-T. Jia, X.-C. Qiu, J. Zhao, C.-J. Yu, R. Zhang, F. Zhu, C.-J. Wang, B.-Q. Jin, et al. A Caspase-6 and Anti-Human Epidermal Growth Factor Receptor-2 (HER2) Antibody Chimeric Molecule Suppresses the Growth of HER2-Overexpressing Tumors J. Immunol., July 1, 2004; 173(1): 61 - 67. [Abstract] [Full Text] [PDF]

				H. Bruhl, J. Cihak, M. Stangassinger, D. Schlondorff, and M. Mack Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: A New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV J. Immunol., February 15, 2001; 166(4): 2420 - 2426. [Abstract] [Full Text] [PDF]

				Y. SATO, N. YAMAUCHI, M. TAKAHASHI, K. SASAKI, J. FUKAURA, H. NEDA, S. FUJII, M. HIRAYAMA, Y. ITOH, Y. KOSHITA, et al. In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate FASEB J, October 1, 2000; 14(13): 2108 - 2118. [Abstract] [Full Text]

				R. J. Kreitman, I. Margulies, M. Stetler-Stevenson, Q.-C. Wang, D. J. P. FitzGerald, and I. Pastan Cytotoxic Activity of Disulfide-stabilized Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) toward Fresh Malignant Cells from Patients with B-Cell Leukemias Clin. Cancer Res., April 1, 2000; 6(4): 1476 - 1487. [Abstract] [Full Text]

				M W J d. Brok, G C de Gast, J H M Schellens, and J H Beijnen Targeted toxins Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 149 - 165. [Abstract] [PDF]